Symbolbild · KI-generiert
Caterpillar Inc.
Stock factsheet
Company data from public sources (TMX Money, Canadian Securities Exchange, Nasdaq screener, Wikidata); every ISIN is verified against its check digit. Where „—“ appears, no verified value exists — we do not publish unverified identifiers. We do not have a verified market capitalisation for this company.
Company profile
Comparable companies
Companies in the Industrials & Manufacturing sector of a similar size.
| Company | Ticker | Exchange | Market cap |
|---|---|---|---|
| Caterpillar Inc. | Euronext Paris | — | |
| Acron Group | AKRN | LSE | — |
| Adidas AG | ADS | Frankfurt | — |
| Aecon | TSX | — | |
| Amcor | AMC | ASX | — |
| Arkema | Euronext Paris | — | |
| Atkins | ATK | LSE | — |
News timeline
- 03.08.2026 Government Satellite Contracts: What Demo Deals Mean for Space Small Caps
- 03.08.2026 AI Security Validation: What Valuation Jumps Really Mean
- 03.08.2026 IND Process & FDA Trialblazer: What Changes for Biotech Small Caps
- 03.08.2026 Defense Contracts in Space: Large Corp vs. Start-Up — What Investors Should Know
- 03.08.2026 Continuous Validation: How AI Is Reshaping the Cybersecurity Market
- 03.08.2026 Laser Communication in Orbit: What Demonstration Contracts Mean for Space Small Caps
- 03.08.2026 AI-Powered Security Validation: Continuous Monitoring Replaces the Annual Pentest
- 03.08.2026 Demonstration Contracts in Orbit: What Navy Awards Mean for Space Start-Ups
- 03.08.2026 Revenue Guidance Upgrade After Approval: What It Means for Biotech Investors
- 03.08.2026 Pivotal Trials in Oncology: What Phase 2/3 Data Really Mean
- 02.08.2026 AI Copyright: When Training Data Becomes a Liability Risk
- 01.08.2026 Laser Communication in Orbit: What Military Contracts Mean for Space Small Caps
- 31.07.2026 SRAM in the AI Era: How Niche Chips Promise Data Center Returns
- 30.07.2026 Defense IPO Postponed: What Really Drives Valuation Expectations
- 29.07.2026 Defense IPO Timing: Why Strong Order Backlogs Aren't Enough
- 28.07.2026 GLP-1 for Addiction: What Phase II Trial Data Really Promise
- 27.07.2026 FDA Reviewers vs. Sponsor: When Regulators and Biotech Read Data Differently
- 24.07.2026 Quantum Correction: Valuation Reset or Fundamental Breakdown?
- 23.07.2026 Megacap Acquisitions in the Quantum Market: Opportunity or Displacement?
- 22.07.2026 Framework Agreement or Firm Order? How Small-Cap Investors Read AI Deals
- 20.07.2026 Dilution in Quantum Small Caps: How to Read a Capital Increase
- 17.07.2026 Pump-and-Dump: How Regulation Dried Up Micro-Cap IPOs
- 16.07.2026 Russell 2000 at Record High: Macro Signals for Small-Cap Investors
- 15.07.2026 AI Platform Pressure: How Cybersecurity Small Caps Defend Their Niche
- 13.07.2026 Micro-Cap Biotech: What Really Drives Share Price Losses
- 09.07.2026 Hong Kong IPO Market: When Megadeals Crowd Out Small-Cap Listings
- 08.07.2026 AI Infrastructure Small Caps: ARR, Margins, and Concentration Risk
- 30.07.2026 Quantum Computing Stocks: When One Contract Moves the Market
- 30.07.2026 FDA Adcom: What a Negative Vote Costs Biotech Investors
- — Biotech IPOs 2026: What an Open IPO Window Really Means
Investor Relations
We link only to primary sources from the company itself and from the regulators. Fields we have not recorded stay empty until a reliable source is available.
Information and education only — not investment advice, not a recommendation and not a financial analysis within the meaning of §85 WpHG or Art. 20 MAR. Investments in small and micro caps are highly speculative; total loss is possible. All information without warranty.